Market research
4568.TSE Daiichi Sankyo Company, Limited
TSE JPY Healthcare
Latest close
As of 28 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 5T
- P/E ratio
- 21.34
- Analyst target
- 4021.25
- Dividend yield
- 2.8%
- Beta
- -0.16
Profile
Company facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- ISIN
- JP3475350009
- Market cap
- 5T
- P/E ratio
- 21.34
- Analyst target
- 4021.25
- Dividend yield
- 2.8%
- Beta
- -0.16
About
About Daiichi Sankyo Company, Limited
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and Datroway for the treatment of HR positive and HER2 negative breast cancer, as well as NSCLC. It also provides Lixiana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe that reduces cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgality for the treatment of migraine attacks; Pralia for the treatment of osteoporosis and bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications and GCTB; Tarlige for the treatment of neuropathic pain; Venofer for the treatment of iron deficiency anemia; Vimpat, an anti-seizure medication; and Reyvow for the treatment of acute migraine attacks. Further, it provides Daichirona, a coronavirus RNA vaccine; Flumist, an intranasal live attenuated influenza vaccine; adsorbed cell culture-derived influenza vaccine; measles rubella combined vaccine; and mump vaccine. The company was formerly known as Sankyo Co. Ltd. and changed its name to Daiichi Sankyo Company, Limited in September 2005. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Chuo, Japan.
Research context
Daiichi Sankyo Company, Limited appears in PyInvesting’s Tokyo Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 4568.TSE discussion.
5 years, 6 months ago
Daiichi Sankyo Company, Limited is currently in a long term downtrend where the price is trading 26.2% below its 200 day moving average.
From a valuation standpoint, the stock is 90.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.4.
Daiichi Sankyo Company, Limited's total revenue sank by 6.8% to $259B since the same quarter in the previous year.
Its net income has dropped by 65.4% to $24B since the same quarter in the previous year.
Finally, its free cash flow fell by 36.3% to $13B since the same quarter in the previous year.
Based on the above factors, Daiichi Sankyo Company, Limited gets an overall score of 1/5.